Acadia Pharma (ACAD) Misses Q1 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
ACADIA Pharmaceuticals Reports First Quarter 2020 Financial Results
May 7, 2020 4:07 PM EDT- 1Q20 Net Sales of $90.1 Million, a 43% Increase Over 1Q19
- On-track to submit supplemental NDA for pimavanserin for the treatment of dementia-related psychosis (DRP) this summer
- Announced worldwide license agreement and collaboration with Vanderbilt University for new central nervous system (CNS) therapeutic program
- 2020 revenue guidance reduced by approximately 5% due to currently anticipated COVID-19 impact
SAN DIEGO--(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative... More
